Understand the source comparison
Peptide Protocol Comparison
GLP-1 Agonists (Semaglutide, Tirzepatide) Gastric emptying delay + ghrelin suppression + AMPK activation High (18–31% reduction in 72 weeks) Strong suppression Moderate (80% of loss from fat) Phase 3 RCTs; FDA-approved GH Secretagogues (CJC-1295, Ipamorelin) P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists (Semaglutide, Tirzepatide)
- Gastric emptying delay + ghrelin suppression + AMPK activation
- High (18–31% reduction in 72 weeks)
- Strong suppression
- Moderate (80% of loss from fat)
- Phase 3 RCTs; FDA-approved
- GH Secretagogues (CJC-1295, Ipamorelin)
- Pulsatile GH release → IGF-1 → hormone-sensitive lipase activation
- Moderate to High (targeted lipolysis without weight loss requirement)
- Minimal
- High (lean mass often increases)
- Observational studies; research-grade
- Dual GLP-1/Glucagon Agonists (Survodutide, Mazdutide)
- GLP-1 satiety + glucagon-driven hepatic fat oxidation
- Very High (exceeds semaglutide by 12–15% in early trials)
- Very strong
- High
- Phase 2 trials ongoing
- Thermogenic Compounds (Tesofensine)
- Norepinephrine/dopamine/serotonin reuptake inhibition → increased NEAT
- Moderate (indirect via caloric expenditure)
- Moderate
- Low to Moderate
- Phase 2 trials; research-grade